



## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 90398

**Title:** Molecular insights into clinical trials for immune checkpoint inhibitors in colorectal cancer: Unravelling challenges and future directions

**Provenance and peer review:** Unsolicited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 05222067

**Position:** Peer Reviewer

**Academic degree:** MD

**Professional title:** Associate Chief Physician, Surgeon

**Reviewer's Country/Territory:** China

**Author's Country/Territory:** United States

**Manuscript submission date:** 2023-12-05

**Reviewer chosen by:** Huo Liu

**Reviewer accepted review:** 2024-01-12 06:34

**Reviewer performed review:** 2024-01-22 02:26

**Review time:** 9 Days and 19 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Novelty of this manuscript</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No novelty
<b>Creativity or innovation of this manuscript</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No creativity or innovation



<b>Scientific significance of the conclusion in this manuscript</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No scientific significance
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous
	Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

**SPECIFIC COMMENTS TO AUTHORS**

Overall Evaluation: Overall, the article is exceptionally detailed and insightful, offering an extensive exploration of the present state of research and the forthcoming advancements in colorectal cancer immunotherapy. The explanations of the findings are lucid and provide profound insights into their scientific significance and relevance within clinical practice. The article maintains a well-structured logical flow and effectively conveys its message in a relatively concise and clear manner. Nevertheless, a few minor revisions are suggested to further enhance the article's quality. Specific Suggestions: Abstract: The abstract summarizes and reflects the work described in the manuscript. It provides information on colorectal cancer (CRC) treatment challenges, the role and limitations of immune checkpoint inhibitors, the importance of pivotal clinical trials, and primary and secondary drug resistance. The abstract highlights the potential and limitations of immunotherapy in the field of CRC and mentions future research directions.. Background: The manuscript adequately describes the background, current status, and significance of the research. Overall, the article provides in-depth background information that highlights current challenges in the field of CRC treatment



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** office@baishideng.com  
**https://**www.wjgnet.com

and the promise of immunotherapy, as well as the importance of future research. Challenges in the field of CRC treatment, especially in advanced or metastatic disease, and potential opportunities for immunotherapy can be appropriately emphasized. This helps to highlight the importance of immunotherapy. In terms of the section elucidating the mechanism of action of immune checkpoint inhibitors in colorectal cancer, if there are relevant recent research advances or clinical trial results, they can be considered to be added to the text to provide more comprehensive information. Conclusion and Discussion: The conclusion and discussion should sum up the current status of immunotherapy in the treatment of colorectal cancer. It should emphasize the accomplishments attained and underscore the challenges that remain to be addressed. Incorporating more up-to-date citations and literature support would strengthen the overall arguments and points. The future directions section can be more comprehensively detailed, encompassing discussions on combination therapies, biomarker research, early colorectal cancer treatment, strategies for overcoming drug resistance, and the implementation of personalized medicine. A brief exploration of the potential implications of these future developments in clinical practice would be beneficial in helping readers understand their potential impact on patient care and survival. These revisions and enhancements will further augment the overall quality and impact of the article.